Jolicoeur F B, Rivest R, St-Pierre S, Drumheller A
Department of Psychiatry, Faculty of Medicine, University of Sherbrooke, Que., Canada.
Brain Res. 1991 Jan 11;538(2):187-92. doi: 10.1016/0006-8993(91)90428-x.
The aim of the present study was to examine the effects of neurotensin in an animal model of Parkinson's disease (PD). Bilateral administration of 6-OHDA in the medial forebrain bundle at the level of the posterolateral hypothalamus of rats resulted in the appearance of the 3 principal neurological signs of PD: hypokinesia, rigidity and tremor. These symptoms were accompanied by severe losses of dopamine and its main metabolites in terminal regions of well-known dopamine pathways. Norepinephrine concentrations were also decreased in several regions but to a lesser extent than dopamine. Intracerebroventricular administration of neurotensin, in doses ranging from 7.5 to 120.0 micrograms, resulted in dose related attenuations of both muscular rigidity and tremors of animals. However, hypokinesia, defined as decreased motor activity was not significantly affected by the peptide. Administration of 120.0 micrograms of [Ala]NT, an inactive analogue of neurotensin, failed to alter any of the 3 neurological signs. Together, these results reveal selective antiparkinson-like effects of neurotensin in an animal model. The theoretical significance of these findings is discussed.
本研究的目的是在帕金森病（PD）动物模型中检测神经降压素的作用。在大鼠下丘脑后外侧水平的内侧前脑束双侧注射6-羟基多巴胺（6-OHDA），导致出现PD的3种主要神经学体征：运动减少、僵硬和震颤。这些症状伴随着多巴胺及其主要代谢产物在著名多巴胺通路终末区域的严重丧失。去甲肾上腺素浓度在几个区域也有所下降，但程度低于多巴胺。脑室内注射剂量范围为7.5至120.0微克的神经降压素，导致动物的肌肉僵硬和震颤出现与剂量相关的减轻。然而，定义为运动活动减少的运动减少并未受到该肽的显著影响。注射120.0微克的神经降压素无活性类似物[Ala]NT，未能改变这3种神经学体征中的任何一种。总之，这些结果揭示了神经降压素在动物模型中的选择性抗帕金森样作用。讨论了这些发现的理论意义。
